TY - JOUR
T1 - Hospitalised patients with breakthrough COVID-19 following vaccination during two distinct waves in Israel, January to August 2021
T2 - a multicentre comparative cohort study
AU - Brosh-Nissimov, Tal
AU - Maor, Yasmin
AU - Elbaz, Meital
AU - Lipman-Arens, Shelly
AU - Wiener-Well, Yonit
AU - Hussein, Khetam
AU - Orenbuch-Harroch, Efrat
AU - Cohen, Regev
AU - Zimhony, Oren
AU - Chazan, Bibiana
AU - Nesher, Lior
AU - Rahav, Galia
AU - Zayyad, Hiba
AU - Hershman-Sarafov, Mirit
AU - Weinberger, Miriam
AU - Najjar-Debbiny, Ronza
AU - Chowers, Michal
N1 - Publisher Copyright:
© 2022 European Centre for Disease Prevention and Control (ECDC). All rights reserved.
PY - 2022/5/19
Y1 - 2022/5/19
N2 - Background: Changing patterns of vaccine breakthrough can clarify vaccine effectiveness. Aim: To compare breakthrough infections during a SARS-CoV-2 Delta wave vs unvaccinated inpatients, and an earlier Alpha wave. Methods: In an observational multicentre cohort study in Israel, hospitalised COVID-19 patients were divided into three cohorts: breakthrough infections in Comirnaty-vaccinated patients (VD; Jun–Aug 2021) and unvaccinated cases during the Delta wave (ND) and breakthrough infections during an earlier Alpha wave (VA; Jan–Apr 2021). Primary outcome was death or ventilation. Results: We included 343 VD, 162 ND and 172 VA patients. VD were more likely older (OR: 1.06; 95% CI: 1.05–1.08), men (OR: 1.6; 95% CI: 1.0–2.5) and immunosuppressed (OR:2.5; 95% CI: 1.1–5.5) vs ND. Median time between second vaccine dose and admission was 179 days (IQR: 166–187) in VD vs 41 days (IQR: 28–57.5) in VA. VD patients were less likely to be men (OR: 0.6; 95% CI: 0.4–0.9), immunosuppressed (OR:0.3; 95% CI: 0.2–0.5) or have congestive heart failure (OR:0.6; 95% CI: 0.3–0.9) vs VA. The outcome was similar between all cohorts and affected by age and immunosuppression and not by vaccination, variant or time from vaccination. Conclusions: Vaccination was protective during the Delta variant wave, as suggested by older age and greater immunosuppression in vaccinated breakthrough vs unvaccinated inpatients. Nevertheless, compared with an earlier post-vaccination period, breakthrough infections 6 months post-vaccination occurred in healthier patients. Thus, waning immunity increased vulnerability during the Delta wave, which suggests boosters as a countermeasure.
AB - Background: Changing patterns of vaccine breakthrough can clarify vaccine effectiveness. Aim: To compare breakthrough infections during a SARS-CoV-2 Delta wave vs unvaccinated inpatients, and an earlier Alpha wave. Methods: In an observational multicentre cohort study in Israel, hospitalised COVID-19 patients were divided into three cohorts: breakthrough infections in Comirnaty-vaccinated patients (VD; Jun–Aug 2021) and unvaccinated cases during the Delta wave (ND) and breakthrough infections during an earlier Alpha wave (VA; Jan–Apr 2021). Primary outcome was death or ventilation. Results: We included 343 VD, 162 ND and 172 VA patients. VD were more likely older (OR: 1.06; 95% CI: 1.05–1.08), men (OR: 1.6; 95% CI: 1.0–2.5) and immunosuppressed (OR:2.5; 95% CI: 1.1–5.5) vs ND. Median time between second vaccine dose and admission was 179 days (IQR: 166–187) in VD vs 41 days (IQR: 28–57.5) in VA. VD patients were less likely to be men (OR: 0.6; 95% CI: 0.4–0.9), immunosuppressed (OR:0.3; 95% CI: 0.2–0.5) or have congestive heart failure (OR:0.6; 95% CI: 0.3–0.9) vs VA. The outcome was similar between all cohorts and affected by age and immunosuppression and not by vaccination, variant or time from vaccination. Conclusions: Vaccination was protective during the Delta variant wave, as suggested by older age and greater immunosuppression in vaccinated breakthrough vs unvaccinated inpatients. Nevertheless, compared with an earlier post-vaccination period, breakthrough infections 6 months post-vaccination occurred in healthier patients. Thus, waning immunity increased vulnerability during the Delta wave, which suggests boosters as a countermeasure.
UR - http://www.scopus.com/inward/record.url?scp=85130315220&partnerID=8YFLogxK
U2 - 10.2807/1560-7917.ES.2022.27.20.2101026
DO - 10.2807/1560-7917.ES.2022.27.20.2101026
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35593161
AN - SCOPUS:85130315220
SN - 1025-496X
VL - 27
JO - Eurosurveillance
JF - Eurosurveillance
IS - 20
ER -